SCHEMBL5857804

SCHEMBL5857804

CC(=O)OC1NC(=O)C1C(C)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.31
CTSS P25774 2/20 0.31
CTSK P43235 2/20 0.31
CTSB P07858 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1143665 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL5857803 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL9046912 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL9313048 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL9045211 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL10416126 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL10553544 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL9546230 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL9423301 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT
SCHEMBL8699325 1.00 CTSL (0.31) CTSLCTSSCTSKCTSBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0197432-A2 Enantioselective process for producing 1-beta-methylcarbapenem antibiotic intermediates MERCK & CO. INC. (US) 1986-10-15 EP claimed
JP-63222156-A None JP disclosed
CN-112961156-A Preparation process of antibiotic drug panipenem 苏州莱克施德药业有限公司 2021-06-15 CN disclosed
WO-2008035153-A2 PROCESS FOR THE PREPARATION OF BETA-LACTAM ANTIBIOTIC ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-03-27 WO disclosed
US-7115595-B2 Carbapenem compounds DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2006-10-03 US disclosed
US-20040063683-A1 Novel carbapenem compounds DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-04-01 US disclosed
EP-0974582-B1 Process for the preparation of 4-substituted azetidinone derivatives TAKASAGO PERFUMERY CO LTD (JP) 2003-02-12 EP disclosed
US-6340751-B1 REACTION OF IMIDAZOLONE WITH AMIDE AND MAGNESIUM COMPOUND TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-01-22 US disclosed
EP-0974582-A1 Process for the preparation of 4-substituted azetidinone derivatives Takasago International Corporation (JP) 2000-01-26 EP disclosed
EP-0171064-B1 Azetidinone derivative and processes for production thereof FUJISAWA PHARMACEUTICAL CO (JP) 1995-07-12 EP disclosed
EP-0502464-A1 Antibacterial condensed carbapenemes GLAXO S.p.A. (IT) 1992-09-09 EP disclosed
US-4960879-A REACTING SUBSTITUTED AZETIDINONE WITH TRANS SUBSTITUTED-METHYL ALKYLACRYLIC ACID AND REDUCING METAL SHIONOGI & CO., LTD. (JP) 1990-10-02 US disclosed
US-4918184-A REACTING 1,3-THIAZOLIDINE-2-THIONE DERIVATIVE WITH TIN TRIFLUOROMETHANESULFONATE TO FORM ENOLATE, REACTING WITH SUBSTITUTED AZETIDINONE LEDERLE (JAPAN), LTD. (JP) 1990-04-17 US disclosed
EP-0336143-A1 A new process for carbapenem intermediates SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1989-10-11 EP disclosed
US-4845210-A Azetidinone derivatives and processes for production thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-07-04 US disclosed
JP-S63222156-A BETA-LACTAM INTERMEDIATE KANEGAFUCHI CHEM IND CO LTD 1988-09-16 JP disclosed
EP-0213610-A1 Azetidin-2-one derivatives and process for production thereof LEDERLE (JAPAN) LTD. (JP) 1987-03-11 EP disclosed
EP-0212404-A1 7-oxo-4-thia-1-azabicyclo [3.2.0] hept-2-ene derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1987-03-04 EP disclosed
US-4639441-A ANTIBACTERIAL PENICILLINS SANKYO COMPANY LIMITED (JP) 1987-01-27 US disclosed
EP-0171064-A1 Azetidinone derivative and processes for production thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063683-A1 Novel carbapenem compounds PTMS, PNISR, LRPPRC CTSL 1528/4885CTSS 1570/4885CTSK 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.